A Study to Evaluate Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Surgical Resection or Ablation

Cancer shared this article with you from Inoreader A Study to Evaluate Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Surgical Resection or Ablation Via MedWorm Cancer & Oncology Clinical Trials Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Camrelizumab;   Drug: Apatinib Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.